Compare RLX Technology Inc (RLX) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
RLX Technology Inc vs Zoetis Inc — how do they compare? RLX Technology Inc trades at $1.73 (market cap $2.10B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 14.4× RLX Technology Inc's market cap, and RLX Technology Inc pays the higher dividend (5.81%). Which is the better fit depends on your goals — on Pluang, investors hold RLX Technology Inc for 35 Days and Zoetis Inc for 70 Days on average.
| RLX | ZTS | |
|---|---|---|
Market Cap | $2.10B | $30.20B |
Volume | 1,079,706 | 6,175,327 |
Sector | Consumer Staples | Health |
52-Week High | $2.57 | $147.53 |
52-Week Low | $1.68 | $69.09 |
Typical Hold Time | 35 Days | 70 Days |
Enterprise Value | $832.26M | $37.76B |
Dividend Yield | 5.81% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RLX Technology trades at $1.72, down 0.58% and near its 52-week low, with a bearish technical signal from moving averages. Fundamentally, the company shows solid profitability with 21.87% net income margin and attractive valuation metrics including P/E of 15.46 and P/B of 0.91. Recent quarterly earnings have consistently missed expectations, though revenue growth remains positive with 2026 projections showing $4.5B revenue and $985M net income.
The stock presents a value opportunity given discounted valuation, but faces headwinds from earnings misses and bearish technicals. International expansion through European acquisitions provides growth catalysts, though execution risks and margin compression require monitoring. Analyst sentiment remains cautious with 100% hold rating, suggesting limited near-term upside potential despite fundamental strengths.
Zoetis (ZTS) trades at $73.08, up 2.14% today, with a bullish technical signal but mixed earnings history including a recent Q1 2026 miss. The stock shows strong profitability with a 27.69% net income margin and 64.91% ROE, while valuation metrics like a P/E of 11.92 appear reasonable. Recent news highlights competitive pressures in the U.S. pet care market, though international segments remain resilient.
The outlook is cautiously optimistic; ZTS faces near-term headwinds from weak U.S. demand and competition, but its industry-leading margins and dominant market position support long-term growth. Risks include pricing erosion and guidance cuts, yet the consensus price target of $87.33 suggests upside potential for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
